vs
Side-by-side financial comparison of Invesco Mortgage Capital Inc. (IVR) and Neuphoria Therapeutics Inc. (NEUP). Click either name above to swap in a different company.
Invesco Mortgage Capital Inc. is the larger business by last-quarter revenue ($21.3M vs $15.0M, roughly 1.4× Neuphoria Therapeutics Inc.). Invesco Mortgage Capital Inc. runs the higher net margin — 242.2% vs 75.1%, a 167.2% gap on every dollar of revenue.
Invesco Ltd. is an American independent investment management company headquartered in Atlanta, Georgia, with branch offices in 20 countries. Its common stock is a constituent of the S&P 500 and trades on the New York Stock Exchange. Invesco operates under the Invesco, Invesco Perpetual, and Powershares brand names.
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
IVR vs NEUP — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.3M | $15.0M |
| Net Profit | $51.5M | $11.3M |
| Gross Margin | — | — |
| Operating Margin | — | 79.8% |
| Net Margin | 242.2% | 75.1% |
| Revenue YoY | 55.4% | — |
| Net Profit YoY | 1368.7% | — |
| EPS (diluted) | $0.72 | $6.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $21.3M | — | ||
| Q3 25 | $17.6M | — | ||
| Q2 25 | $17.7M | — | ||
| Q1 25 | $18.8M | $15.0M | ||
| Q4 24 | $13.7M | — | ||
| Q3 24 | $7.5M | — | ||
| Q2 24 | $8.6M | — | ||
| Q1 24 | $7.0M | — |
| Q4 25 | $51.5M | — | ||
| Q3 25 | $53.5M | — | ||
| Q2 25 | $-23.3M | — | ||
| Q1 25 | $19.6M | $11.3M | ||
| Q4 24 | $3.5M | — | ||
| Q3 24 | $40.7M | — | ||
| Q2 24 | $-13.5M | — | ||
| Q1 24 | $29.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 79.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | 242.2% | — | ||
| Q3 25 | 303.6% | — | ||
| Q2 25 | -131.6% | — | ||
| Q1 25 | 104.4% | 75.1% | ||
| Q4 24 | 25.6% | — | ||
| Q3 24 | 542.2% | — | ||
| Q2 24 | -155.9% | — | ||
| Q1 24 | 415.9% | — |
| Q4 25 | $0.72 | — | ||
| Q3 25 | $0.74 | — | ||
| Q2 25 | $-0.40 | — | ||
| Q1 25 | $0.26 | $6.55 | ||
| Q4 24 | $-0.09 | — | ||
| Q3 24 | $0.63 | — | ||
| Q2 24 | $-0.38 | — | ||
| Q1 24 | $0.49 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $56.0M | $17.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $797.5M | $26.0M |
| Total Assets | $6.5B | $30.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $56.0M | — | ||
| Q3 25 | $58.5M | — | ||
| Q2 25 | $59.4M | — | ||
| Q1 25 | $42.9M | $17.0M | ||
| Q4 24 | $73.4M | — | ||
| Q3 24 | $48.3M | — | ||
| Q2 24 | $58.8M | — | ||
| Q1 24 | $59.9M | — |
| Q4 25 | $797.5M | — | ||
| Q3 25 | $769.6M | — | ||
| Q2 25 | $709.4M | — | ||
| Q1 25 | $759.2M | $26.0M | ||
| Q4 24 | $730.7M | — | ||
| Q3 24 | $857.0M | — | ||
| Q2 24 | $759.2M | — | ||
| Q1 24 | $785.6M | — |
| Q4 25 | $6.5B | — | ||
| Q3 25 | $6.0B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $6.2B | $30.7M | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.1B | — | ||
| Q1 24 | $5.2B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $157.1M | $11.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 3.05× | 1.02× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $157.1M | — | ||
| Q3 25 | $37.3M | — | ||
| Q2 25 | $40.6M | — | ||
| Q1 25 | $19.3M | $11.5M | ||
| Q4 24 | $183.2M | — | ||
| Q3 24 | $30.8M | — | ||
| Q2 24 | $33.0M | — | ||
| Q1 24 | $57.5M | — |
| Q4 25 | 3.05× | — | ||
| Q3 25 | 0.70× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.98× | 1.02× | ||
| Q4 24 | 52.24× | — | ||
| Q3 24 | 0.76× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.97× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
